Insilico completes first-in-human dosing in phase I clinical study of AI-driven NLRP3 inhibitor ISM8969, achieving first clinical milestone in collaboration with Hgtia - EurekAlert!
Insilico Medicine completes first-in-patient dosing of ISM3412, the novel MAT2A inhibitor for the treatment of locally advanced/metastatic solid tumors - EurekAlert!
